Literature DB >> 7742433

Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome.

G A Noskin1, L R Peterson, J R Warren.   

Abstract

The incidence of enterococcal bacteremia due to Enterococcus faecium is increasing. To understand the clinical significance of E. faecium bacteremia, we compared 16 patients who were bacteremic due to E. faecium to 56 patients who were bacteremic due to Enterococcus faecalis. E. faecium bacteremia developed most frequently in severely ill patients with fever or hypothermia accompanied by CNS, cardiovascular, and/or pulmonary dysfunction, while E. faecalis bacteremia occurred most often in less seriously ill patients. Nosocomial acquisition, cancer, neutropenia, renal insufficiency, current corticosteroid therapy, and previous treatment with broad-spectrum antibiotics were significantly more frequently associated with E. faecium bacteremia. Mortality was significantly higher among patients infected with E. faecium than among those infected with E. faecalis (50% vs. 11%; P = .001); this was true particularly among patients with monomicrobial or nosocomial bacteremia, those who had previously received antibiotic treatment, and those with cancer. Death due to enterococcal bacteremia was observed only among severely ill patients. These findings suggest that E. faecium often infects debilitated patients and that such infection appears to be a significant factor contributing to mortality.

Entities:  

Mesh:

Year:  1995        PMID: 7742433     DOI: 10.1093/clinids/20.2.296

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  36 in total

Review 1.  Relationships between enterococcal virulence and antimicrobial resistance.

Authors:  L M Mundy; D F Sahm; M Gilmore
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Survival of Enterococcus faecalis in mouse peritoneal macrophages.

Authors:  C R Gentry-Weeks; R Karkhoff-Schweizer; A Pikis; M Estay; J M Keith
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

4.  Resistant enterococci--mechanisms, laboratory detection and control in hospitals.

Authors:  J J Wade; A H Uttley
Journal:  J Clin Pathol       Date:  1996-09       Impact factor: 3.411

Review 5.  Pathogenicity of Enterococci.

Authors:  Elizabeth Fiore; Daria Van Tyne; Michael S Gilmore
Journal:  Microbiol Spectr       Date:  2019-07

Review 6.  Enterococcus faecium in hospitals.

Authors:  J J Wade
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-02       Impact factor: 3.267

Review 7.  Current guidelines for the treatment and prevention of nosocomial infections.

Authors:  E Bergogne-Bérézin
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

8.  The acute-phase response impairs host defence against Enterococcus faecium peritonitis.

Authors:  Masja Leendertse; Rob J L Willems; Ida A J Giebelen; Petra S van den Pangaart; Marc J M Bonten; Tom van der Poll
Journal:  Immunology       Date:  2008-10-30       Impact factor: 7.397

9.  Antimicrobial activity of Bauhinia tomentosa and Bauhinia vahlii roots.

Authors:  Swarnalatha Dugasani; Madhu Katyayani Balijepalli; Satyanarayana Tandra; Mallikarjuna Rao Pichika
Journal:  Pharmacogn Mag       Date:  2010-07       Impact factor: 1.085

Review 10.  Are there patients with peritonitis who require empiric therapy for enterococcus?

Authors:  S Harbarth; I Uckay
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-01-21       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.